The main objective of the Sencell Implantable Miniaturized Osmotic Sensor Device is to provide a convenient, efficient, reliable, painless, accurate and durable continuous glucose measurement (CGM) solution at a low cost for daily use to diabetics. The unique and advanced technology of Sencell offers a novel technology for the global market.
The Sencell glucose monitoring system includes an osmotic pressure sensor (sensor core), transmitter (sensor electronics) and a mobile medical application (reader) to continuously measure glucose in the interstitial fluid. The miniaturized device is implanted with a syringe into the subcutaneous space of the patient’s arm, wrist or other suitable body site and requires no battery or wires for the sensor operation and for communication with the transmitter.
The ultimate goal for diabetics is “to live a normal life”. Today there are only short-term semi-invasive products but no long-term implantable sensors for measuring glucose on the market. The Sencell glucose monitoring system is implanted in the subcutaneously space on the arm wrist or other subcutaneous places in the body with no sensor part protruding from the skin. After insertion, the sensor functions noninvasively, automatically, and continuously for a long term. The ultimate goal is a minimum duration of 6 months. Encased in a biocompatible material, the device utilizes a unique osmotic pressure assessment technology, which translates the signal of a physical miniaturized osmotic pressure cell into an accurate glucose reading that can be used to determine the insulin doses and to generate warning signals in case of hypo- or hyperglycaemia.
All major innovations are patented. Lifecare conducted in vivo studies in November 2015 and August 2016. These pre-clinical studies verified the proof-of-concept of its core technology.
Sencell represents a breakthrough in glucose measurement and administration of diabetes by combining world-class development and knowledge within areas such as chemistry, human biology, MEMS/NEMS and electronics into a patented solution. This is done through new technologies like 3D nanotech transmitter printing and the combination of certain molecules/lectins with human biology. Lifecare will collaborate with the foremost global expertise in these areas through signed service agreements.